These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27215447)

  • 21. [The future of asthma therapy].
    Solèr M
    Schweiz Med Wochenschr; 2000 Feb; 130(8):277-81. PubMed ID: 10726286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
    Walsh GM
    Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab: overview of pharmacology and efficacy in asthma.
    Ledford DK
    Expert Opin Biol Ther; 2009 Jul; 9(7):933-43. PubMed ID: 19527111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lebrikizumab for the treatment of asthma.
    Antoniu SA
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH; Ashman C; Cahn AP; Locantore NW; Overend P; Pouliquen IJ; Serone AP; Wright TJ; Jenkins MM; Panesar IS; Thiagarajah SS; Wenzel SE
    J Allergy Clin Immunol; 2014 Apr; 133(4):989-96. PubMed ID: 24582316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What goes up must come down: biomarkers and novel biologicals in severe asthma.
    Hilvering B; Pavord ID
    Clin Exp Allergy; 2015 Jul; 45(7):1162-9. PubMed ID: 25640208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma.
    Li H; Wang K; Huang H; Cheng W; Liu X
    PLoS One; 2019; 14(1):e0211790. PubMed ID: 30703143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunopathogenesis of bronchial asthma.
    Buc M; Dzurilla M; Vrlik M; Bucova M
    Arch Immunol Ther Exp (Warsz); 2009; 57(5):331-44. PubMed ID: 19688187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
    Fajt ML; Wenzel SE
    J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted anti-IL-13 therapies in asthma: current data and future perspectives.
    Ntontsi P; Papathanassiou E; Loukides S; Bakakos P; Hillas G
    Expert Opin Investig Drugs; 2018 Feb; 27(2):179-186. PubMed ID: 29334288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma.
    Martin PL; Fisher D; Glass W; O'Neil K; Das A; Martin EC; Li L
    Int J Toxicol; 2008; 27(5):351-8. PubMed ID: 19037805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Omralizumab (Xolair) in severe persistent allergic asthma].
    Schleich F; Manise M; Louis R
    Rev Med Liege; 2009; 64(5-6):313-7. PubMed ID: 19642466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
    Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
    Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.